Aug 2026· ACS Bio & Med Chem Au· 0 citations· 29 references
Abstract
Proteolysis-targeting chimeras (PROTACs) can induce degradation of otherwise challenging proteins, but their large size and unfavorable physicochemical properties often limit cellular delivery. We designed PROTAC–peptide conjugates containing a nona-arginine cell-penetrating peptide (R9), a redox-sensitive disulfide linker, and an aromatic-rich peptide sequence previously described as an endosomal escape domain (EED). The EED sequence was positioned at either the N- or C-terminus to examine how peptide-domain arrangement affects intracellular fluorescence, payload release, and BRD4 degradation. At 10 and 100 nM, the C-terminal variant MZ1-R9-EED produced a greater reduction in BRD4 abundance at 24 h than MZ1-R9 and MZ1-EED-R9, although the two-concentration comparison did not permit determination of DC50, Dmax, or hook effects. FAM-based flow cytometry yielded pH-sensitive cell-associated fluorescence signals that could not be interpreted as an absolute measure of total cellular uptake. Qualitative confocal microscopy showed punctate fluorescence with apparent LysoTracker overlap but did not provide quantitative evidence of endosomal escape. Under a defined cell-free reducing condition, MZ1-R9-EED underwent faster apparent disulfide cleavage, with a half-life of 0.21 h versus 0.36–0.47 h for the other conjugates, and yielded higher apparent intracellular free MZ1 levels under identical analytical conditions. Square-wave voltammetry revealed no substantial differences in reduction potential, whereas molecular dynamics simulations suggested a possible contribution of local steric accessibility. These findings associate peptide-domain positioning with cleavage kinetics, free-payload levels, and BRD4 reduction, identifying domain arrangement as a design variable for disulfide-linked PROTAC–peptide conjugates without establishing cleavage as the rate-limiting or causal mechanism.
Proteolysis-targeting chimeras (PROTACs) promote targeted protein degradation by inducing a transient ternary complex between a protein of interest and an E3 ubiquitin ligase. Despite the clinical promise of these event-driven therapeutics, defining the conformational landscape and interfacial organization of these com...
Evan N. Whitford, Joshua D. Gilbert, Marius M. Kostelic et al.· bioRxiv· 0 citations
Vaccinia-related kinase 1 (VRK1) is an oncogenic serine/threonine kinase implicated in tumor progression, yet it remains an intractable target for catalytic degradation. Herein, we report the structure-guided design of a first aptamer–PROTAC chimera for potent and selective degradation of VRK1. Through structure-guided...
Yangfang Yun, Ya-Qing Gao, Yang Shi et al.· Chemical Science· 1 citation
A mammalian fluorescence resonance energy transfer (FRET) based high-throughput reporter system is developed to quantitatively measure 2A activity across large libraries of natural and engineered 2A peptides and provides mechanistic and evolutionary insights into how nascent peptide–ribosome exit tunnel interactions me...
Adesh Baral, Aditi Kothiala, K. X. Zhong et al.· bioRxiv· 0 citations
It is demonstrated that the C-terminal EAAAK motif in IPB29—originally designed as a rigid linker connecting the peptide backbone to the lipid moiety—is critical for its antiviral activity and functions via the endosomal fusion pathway.
Zhi-Xin Yao, Yuan-Mei Zhu, Nian Liu et al.· Journal of Virology· 0 citations
Disulfide-rich peptides (DRPs) are attractive drug development scaffolds due to their exceptional stability and specificity. Regioselective disulfide bond formation is often achieved via orthogonal Cys protecting groups or strategic Pro placement. However, Cys protection strategies are labor-intensive and low-yielding,...
Declan T. Cook, Kish R. Adoni, Konstantinos Thalassinos et al.· Analytical Chemistry· 0 citations
Proteolysis-targeting chimeras (PROTACs) are emerging as a promising strategy for antiviral drug development and are mechanistically distinct from classical small-molecule inhibitors. Many PROTAC designs targeting viral proteases, such as the SARS-CoV-2 main protease (Mpro), employ warheads derived from active-site inh...
C. Veeck, Luna C. Schmacke, Jasmin Jekkel et al.· Journal of Visualized Experi...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.